An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study

• Published in: The International journal of drug policy 2022-04, Vol.102, p.103580-103580, Article 103580
• Main Authors: Mirzazadeh, Ali, Hosseini-Hooshyar, Samira, Shahesmaeili, Armita, Sharafi, Heidar, Shafiei, Mohammad, Zarei, Jasem, Mousavian, Ghazal, Tavakoli, Fatemeh, Ghalekhani, Nima, Shokoohi, Mostafa, Khezri, Mehrdad, Mehmandoost, Soheil, Shojaei, Mohammad Reza, Karamouzian, Mohammad, Briceno, Alya, Morris, Meghan D., Alavian, Seyed Moayed, Haghdoost, Ali-Akbar, Sharifi, Hamid, Page, Kimberly A.
• Format: Article
• Language: English
• Subjects: Adult; Antiviral Agents - therapeutic use; Antiviral drugs; Clinics; Community; Community-based model; DAA therapy; Diagnostic tests; Drop-in centers; Drug policy; Drug use; Drug Users; Drugs; Elimination; Female; HCV elimination; HCV prevalence; HCV treatment; Hepacivirus - genetics; Hepatitis; Hepatitis C; Hepatitis C - diagnosis; Hepatitis C - drug therapy; Hepatitis C - epidemiology; Hepatitis C Antibodies; High risk; Hospitals; Humans; Integrated model of care; Iran; Iran - epidemiology; Male; Medical diagnosis; Medical screening; Medical treatment; Onsite; People who inject drugs; Pilot Projects; Recruitment; RNA - therapeutic use; Substance Abuse, Intravenous - epidemiology; Uptake; Venipuncture
• ISSN: 0955-3959; 1873-4758
• DOI: 10.1016/j.drugpo.2022.103580

People who inject drugs (PWID) are at high risk for hepatitis C virus (HCV) infection and its complications in many countries, including Iran. This pilot study aimed to evaluate the effect of a community-based HCV model of care on HCV testing and treatment initiation among PWID in Kerman, Iran. This study is part of the Rostam study and is a non-randomized trial evaluating the effect of on-site HCV- antibody rapid testing, venipuncture for HCV RNA testing, and treatment eligibility assessment on HCV testing and treatment initiation among PWID. Recruitment, interviews, and HCV screening, diagnosis, and treatment were all conducted at a community-based drop-in center (DIC) serving PWID clients. A total of 171 PWID (median age of 39 years and 89.5% male) were recruited between July 2018 and May 2019. Of 62 individuals who were HCV antibody positive, 47 (75.8%) were HCV RNA positive. Of RNA-positive individuals, 36 (76.6%) returned for treatment eligibility assessment. Of all the 36 participants eligible for treatment, 34 (94.4%) initiated HCV antiviral therapy. A sustained virologic response at 12 weeks post-treatment was 76.5% (26/34) in the intention-to-treat (ITT group) analysis and 100% (23/23) in the per-protocol (PP group) analysis. Our integrated on-site community-based HCV care model within a DIC setting suggested that HCV care including HCV testing and treatment uptake can be successfully delivered outside of hospitals or specialized clinics; a model which is more likely to reach PWID and can provide significant progress towards HCV elimination among this population.